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Background: The rapid emergence and dissemination of carbapenem resistance in Enterobacteriaceae complicates
the treatment of infections caused by these organisms.
Methods: We collected clinical isolates with meropenem inhibition zones of≤ 22 mm from January 1, 2009,
through December 31, 2010. We attempted to amplify the NDM-1 gene from these isolates and conducted the
modified Hodge test (MHT). The minimal inhibitory concentration (MIC) of the MHT-positive strains was determined
by the agar disk dilution method. The carbapenemase-encoding resistance genes of these strains were examined
using polymerase chain reaction (PCR) analysis and a sequencing strategy to characterize these enzymes. The clonal
relationship among isolates was analyzed by pulsed-field gel electrophoresis (PFGE).
Results: Among the 158 Enterobacteriaceae isolates that were collected, there were no NDM-1-positive strains and 26
MHT-positive strains. Among the latter, 18 strains were IMP-4-positive, and 1 was KPC-2-positive. In addition, 15 of the
IMP-4-positive Klebsiella pneumoniae strains belonged to 4 PFGE genotypes, with 8 strains having the same genotype.
Conclusion: These results suggest that nosocomial infections are one of the main reasons for the spread of these
resistant strains.
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Enterobacteriaceae are the most common pathogenic bac-
teria. Recently, the emergence of resistant pathogenic bac-
teria has caused significant problems for the clinical
treatment of enterobacterial infections worldwide. There are
many mechanisms leading to this resistance [1]. Extended-
spectrum β-lactamase (ESBL)-producing pathogenic entero-
bacteria is a serious problem for antibiotic management
because the ESBL genes are easily transferred from one
organism to another via plasmids or other mobile genetic
elements in combination with non-β-lactam resistance
mechanisms, leading to multidrug-resistant isolates [1,2].
Carbapenem antibiotics are a class of β-lactam antibi-
otics that are often used as a last resort for treating entero-
bacterial resistance. However, an increasing number of
studies are reporting carbapenem-resistant enterobacteria
[2-4]. Carbapenem-resistant enterobacterial infections are
now clearly associated with significant morbidity and* Correspondence: fengj_sun@163.com; peiyuan_xia@aliyun.com
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unless otherwise stated.mortality. However, few studies have monitored the
spread of these Enterobacteriaceae. Here, we report the
spread of IMP-4-producing enterobacteria in a hospital
in Chongqing, China.Materials and methods
Study design
The study period was from January 1, 2009, through
December 31, 2010. All samples were collected from the
Southwest Hospital, which is one of the largest teaching
hospitals in Chongqing, China, with approximately 3000
beds. The bacterial isolates were identified in the clinical
microbiology laboratory using standard biochemical tests
and the Vitek system (BioMérieux, Hazelwood, MO). If
the meropenem inhibition zone was ≤ 22 mm, an at-
tempt was made to amplify the NDM-1 gene from the
strain, and the strain was evaluated with the modified
Hodge test (MHT) [5]. The MHT has been widely used
to screen for carbapenemase activity because it directly
analyzes this activity. If the sample was either MHT-
positive or NDM-1-positive, the medical records andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 The primers used to amplify the carbapenemase
genes by PCR
Gene Primer Size (bp) Reference
IMP-1 F 5‘-atgagcaagttatctgtattctttat-3’ 741 9
IMP-1R 5‘-ttagttgcttagttttgatggttt-3’
KPC-1 F 5‘-tcgccgtctagttctgctgtctt-3’ 965 9
KPC-1R 5‘-ccgcgcagactcctagcctaa-3’
NDM-1 F 5‘-tcaccgagattgccgagcga-3’ 457 9
NDM-1R 5‘-gggcagtcgcttccaacggt-3’
VIM-1 F 5‘- ggtcgcatatcgcaacgcagt-3’ 636 9
VIM-1R 5‘-cggcgactgagcgatttttg-3’
IMI-1 F 5‘- ccattcacccatcacaac-3’ 440 9
IMI-1R 5‘- ctaccgcataatcatttgc-3’
SPM-1 F 5‘- ctgcttggattcatgggcgc-3’ 783 1
SPM-1R 5‘- ccttttccgcgaccttgatc-3’
OXA-23 F 5‘- acttgctatgtggttgcttctctt-3’ 797 9
OXA-23R 5‘- ttcagctgttttaatgatttcatca-3’
OXA-24 F 5‘- cgatcagaatgttcaagcgc-3’ 559 9
OXA-24R 5‘- acgattctcccctctgcgc-3’
OXA-48 F 5‘- ttggtggcatcgattatcgg-3’ 744 1
OXA-48R 5‘- gagcacttcttttgtgatggc-3’
OXA-51 F 5‘- tccaaatcacagcgcttcaaaa-3’ 639 9
OXA-51R 5‘- tgaggctgaacaacccatcca-3’
OXA-58 F 5‘- cgatcagaatgttcaagcgc-3’ 529 1
OXA-58R 5‘- acgattctcccctctgcgc-3’
Chen et al. Annals of Clinical Microbiology and Antimicrobials 2014, 13:42 Page 2 of 6
http://www.ann-clinmicrob.com/content/13/1/42laboratory data for the associated patient were retrospect-
ively reviewed using records available from the Southwest
Hospital information system and from the microbiology
laboratory. In this study, each isolate was collected from a
different patient. This study was approved by the Ethics
Committee of the Third Military Medical University
(Approval number, KY200508).
Susceptibility testing
Bacterial isolates were identified according to standard
methods and tested against various antibiotics by the disk
diffusion method; the zone diameters were interpreted ac-
cording to the Clinical and Laboratory Standards Institute
(CLSI) guidelines. The minimal inhibitory concentration
(MIC) was evaluated for MHT-positive and NDM-1-
positive strains. The MIC was determined by the agar disk
dilution method in freshly prepared test medium (MH) ac-
cording to the 2010 guidelines of the CLSI, and Escheri-
chia coli strain ATCC 25922 was used as the control
strain for the MIC testing. The resistance rate refers to the
number of resistant strains divided by the total number of
strains. The susceptible strains include those that are fully
susceptible and those with an intermediate susceptible ac-
cording to the CLSI standard.
PFGE
All Klebsiella pneumoniae isolates were analyzed by
pulsed-field gel electrophoresis (PFGE) using the contour-
clamped homogeneous electric field (CHEF) technique,
which is similar to the method described by Shen et al. [6]
and Gouby et al. [7]. The XbaI restriction enzyme was
used (Takara, DaLian, China). DNA fragments were sepa-
rated by electrophoresis in a 1% agarose III gel (Bio-Rad,
China) with a CHEF apparatus (CHEF Mapper XA, Bio-
Rad). The electrophoresis was performed at 14°C and 6 V/
cm and with alternating pulses at a 120° angle in a 2- to
40-s pulse-time gradient for 24 h. The typing criteria were
based on the protocol described by Shen et al. [6] and
Tenover et al. [8].
Carbapenemase analysis
Carbapenemase genes that are common in China were amp-
lified by PCR with the primers shown in Table 1. NDM-1-,
IMI-1-, SPM-1-, IMP-1-, KPC-1-, VIM-1-, and OXA-type-
positive strains were preserved in our laboratory [9]. The se-
quence analyses were performed using the BLAST program
available on the National Center for Biotechnology Informa-
tion server (http://www.ncbi.nlm.nih.gov/).
Results
From January 1, 2009 to December 31, 2010, 158 Entero-
bacteriaceae isolates (92K. pneumoniae, 9 E. coli, and 57
Enterobacter cloacae) with reduced susceptibility to imipe-
nem were identified in the hospital. Only 1 isolate of eachbacterial species was selected per patient, and all of the
strains were collected from patients 48 h after admission.
Among the 158 Enterobacteriaceae, the Hodge test was
positive for 26 strains (20K. pneumoniae, 4 E. coli, and 2
E. cloacae), and no strain was NDM-1-positive. The fea-
tures of these isolates and the patients are presented in
Table 2. Among twenty-six clinical strains, eighteen iso-
lates were IMP-4 positive, and one was KPC-2 positive.
Seventeen strains were from sputum, and sixteen strains
were from pediatrics. All the strains of group A PFGE
genotype were from pediatrics.
The results of MIC range, MIC50 and MIC90 analyses
are presented in Table 3. We used previously described
PCR reactions to screen for carbapenem-hydrolyzing β-
lactamase genes. The PCR reactions for the IMP-4 and
KPC-2 genes were positive [9]. The major epidemic pat-
tern A consisted of ten IMP-4-positive isolates from the
Department of Pediatrics. However, the only one KPC-2-
positive strain was collected from the Department of
Neurology.
XbaI pulsed-field gel electrophoresis was then used to
study the genetic relatedness of the 20 K. pneumoniae
isolates. The results are presented in Figure 1, and they
suggest nosocomial transmission.
Table 2 Features of the Enterobacteriaceae clinical isolates
Collection
date







1 2009-9-28 Kpn Male 31 days Sputum 11 Pediatrics Acute pneumonia A IMP-4 2 1
2 2009-10-7 Kpn Female 2 days Blood 7 Pediatrics Neonatal pneumonia A IMP-4 4 2
3 2009-12-19 Kpn Female 10 days Sputum 6 Pediatrics Neonatal pneumonia A IMP-4 <1 <1
4 2009-12-26 Kpn Male 56 years Abdominal fluid 31 Hepatobiliary department Abdominal infection C - 8 8
5 2010-4-3 Kpn Male 30 days Sputum 8 Pediatrics Acute pneumonia E IMP-4 64 128
6 2010-4-10 Eco Female 57 years Abdominal fluid 21 ICU Severe acute pancreatitis - IMP-4 4 2
7 2010-5-15 Ecl Male 15 days Sputum 22 Pediatrics Neonatal pneumonia - IMP-4 4 8
8 2010-5-24 Kpn Male 58 minutes Sputum 11 Pediatrics Neonatal pneumonia A IMP-4 4 4
9 2010-5-26 Kpn Male 38 minutes Sputum 11 Pediatrics Neonatal pneumonia E IMP-4 16 16
10 2010-5-29 Kpn Male 2 months Sputum 21 Pediatrics Acute pneumonia B IMP-4 128 64
11 2010-5-29 Kpn Male 6 hours Sputum 12 Pediatrics Neonatal pneumonia A IMP-4 4 4
12 2010-6-3 Kpn Female 50 minutes Sputum 88 Pediatrics Neonatal pneumonia A - 4 2
13 2010-6-29 Kpn Female 19 days Sputum 12 Pediatrics Neonatal pneumonia A IMP-4 <1 <1
14 2010-6-29 Eco Male 56 years Ascites 37 Department of hepatobiliary Carcinoma of the pancreatic head - IMP-4 <1 <1
15 2010-7-3 Kpn Male 20 years Sputum 49 ICU Open craniocerebral injury E - 4 4
16 2010-7-3 Eco Male 79 years Sputum 6 Department of gastroenterology Chordapsus, pneumonia - - <1 <1
17 2010-7-17 Kpn Male 1 hour Sputum 9 Pediatrics Neonatal pneumonia A IMP-4 1 <1
18 2010-7-21 Kpn Male 1 hour Sputum 7 Pediatrics Neonatal pneumonia A - 2 1
19 2010-7-21 Eco Female 44 years Blood 46 Department of hepatobiliary Congenital choledochus cyst - - 2 1
20 2010-7-23 Kpn Female 16 days Sputum 10 Pediatrics Neonatal pneumonia E IMP-4 32 16
21 2010-7-23 Kpn Male 1 hour Sputum 18 Pediatrics Neonatal pneumonia C IMP-4 32 32
22 2010-7-23 Kpn Male 60 years Blood 46 ICU Multiple injuries E IMP-4 8 8
23 2010-10-11 Kpn Female 26 days Sputum 12 Pediatrics Neonatal pneumonia A IMP-4 2 2
24 2010-10-17 Ecl Male 54 years Wound 48 ICU Penetrating wound - - 1 <1
25 2010-10-20 Kpn Female 69 years Wound 17 Department of neurology Pneumonia D KPC-2 16 8
























Table 3 MIC range, MIC50 and MIC90 for antibiotics tested against Enterobacteriaceae
Antimicrobial agent MIC range (μg/ml) MIC50 (μg/ml) MIC90 (μg/ml)
Imipenem 1 < − 128 4 16
Meropenem 1 < − 64 2 16
Ceftazidim 1 < − > 512 512 > 512
Ceftriaxone 1 < − > 512 > 512 > 512
Piperacillin/tazobactam 1 < − > 512 128 512
Piperacillin 1 − > 512 > 512 > 512
Ciprofloxacin 1 < − 64 4 32
Levofloxacin 1 < −128 8 32
Gentamicin 1 < − >512 8 64
Tobramycin 1 < − >512 4 64
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In the present study, we analyzed the carbapenemase genes
and assessed the spread of IMP-4-positive enterobacteria in
a hospital in Chongqing, China. IMP-4 is a common MBL
and was first reported in Acinetobacter baumannii in Hong
Kong, China; it subsequently spread throughout the world,
particularly to mainland China and Australia [10,11]. IMP-Figure 1 PFGE analysis of genomic DNA from isolates of K. pneumoni4 has been reported in enterobacteria in China [12] but has
not been found in Southwestern China. Previously, we
found that the IMP-4 gene existed in A. baumannii (data
were not shown) and Pseudomonas aeruginosa [9]. Since
2007, we have detected the carbapenemase genes in entero-
bacteria. In 2009, we found the first carbapenemase gene,
IMP-4, which we subsequently showed to be spreadingae.
Chen et al. Annals of Clinical Microbiology and Antimicrobials 2014, 13:42 Page 5 of 6
http://www.ann-clinmicrob.com/content/13/1/42among enterobacteria. However, IMP-8 has been reported
in Chongqing despite the presence of IMP-4 [13]. These re-
sults suggested that IMP-4 may be transferred to entero-
bacteria from other bacteria in our hospital. After the first
IMP-4-positive K. pneumoniae strain was found in the
Pediatrics Unit, 18 IMP-4-positive enterobacteria were
identified, including one E. cloacae and two E. coli strains.
KPC-2 is common in the coastal cities of China, such as
Hangzhou and Shanghai [14,15]. Only one KPC-2-positive
strain was found among the clinical isolates, and it was re-
ported in The First Affiliated Hospital of Chongqing
Medical University, Chongqing [13]. Since then, we have
not found another KPC-2-positive strain. Thus, the KPC-2-
positive strain may have been present in the patient prior to
hospitalization and not acquired from a hospital ward.
For seven MHT-positive strains, no carbapenemase
gene was amplified. The MHT has negative and positive
likelihood rates, and the positive likelihood rate in our
experiment is higher than that in a previous report [16].
Here, we only tested for the commonly appearing carba-
penemase genes in China, so it is possible that these
seven strains have other resistance genes. The MHT-
and IMP-4-positive strains exhibited low-level resistance
and even susceptibility to carbapenems in our study, and
Nordmann reported similar results [2]. Thus, the highly
resistant strains carrying IMP-4 must have additional
mechanisms for carbapenem resistance, such as outer-
membrane permeability defects, other resistance genes,
or target alteration. Therefore, to treat carbapenemase-
positive strains, carbapenem antibiotics, although not
the preferred choice, may be the only choice.
The PFGE revealed genetic diversity among the 20K.
pneumoniae isolates, which belonged to five PFGE types.
Ten strains of K. pneumoniae shared the same PFGE type.
The phenomenon of the same clones spreading within the
same wards or throughout different wards during the
same period was observed. The same clones had similar
resistance results but slightly different MIC results, sug-
gesting that some features of the bacteria had changed as
they spread and replicated or that these bacteria could eas-
ily exchange mobile genetic elements. These findings indi-
cated that the decreased susceptibility to carbapenems in
K. pneumoniae may arise by the stepwise accumulation of
multiple carbapenem resistance determinants in different
clones. These results suggest that this type of infection can
be classified as a hospital-derived infection. Therefore,
controlling hospital infections is a method for reducing
the accumulation of bacteria resistance determinants.
The average hospital stay of the patients with these iso-
lates was 23.1 days, while the average hospital stay of all
patients in our hospital was 9.8 days. Long-term acute care
hospitals (LTACHs) may play a particularly important role
in the spread of KPC-producing Enterobacteriaceae, par-
ticularly among neonates or patients with a serious illnesswho have a reduced immune system functional capacity
and who are undergoing invasive examinations or treat-
ments. Our results support the conclusions reported by
Endimiani [17]. Thus, for patients with a high risk of in-
fection, reinforcement of infection control measures
based on the guidance for carbapenemase-producing
Enterobacteriaceae prevention [17] with early warning
is particularly critical and should include promotion of
hand hygiene. In addition, the immediate initiation of
contact precautions is necessary, which can lead to a
considerable reduction in hospital-acquired carbapene-
mase producers. Our findings also suggest that a signifi-
cant containment of carbapenem-resistant K. pneumoniae
strains from the environment is possible with the imple-
mentation of a comprehensive infection control interven-
tion program that includes active surveillance, carrier
isolation/cohorting, and a dedicated staff to treat individ-
uals who become infected. The advent of these tests has
enabled the early detection of clonal strains that are likely
to be introduced into our hospital, especially from patients
with previous hospitalizations. In the future, we will
analyze more diverse strains and resistant genes. After in-
fection control measures are reinforced, we will conduct
additional infection control studies to test the effects of re-
inforcing infection control measures.
Taken together, these findings reveal the process in-
volved in the recent spread of IMP-4 in our hospital.
Carbapenem-resistant enterobacteria have become a sig-
nificant concern in our hospital. The presence of carba-
penemases, such as KPC-2 and IMP-4, may have played
a significant role in the development of these resistant
strains. Cooperation among the clinical microbiology la-
boratory, the infection control team, and the medical
and nursing staff is vital for the design and implementa-
tion of appropriate infection control measures for
carbapenemase-producing pathogens. The use of active
surveillance as part of this multifactorial intervention
may also aid in decreasing the secondary transmission
rates of imported genes. Other interventions, such as
shortening the average length of hospital stays, may fur-
ther augment these infection control actions. Examining
whether our interventions change the prevalence of
other, less common, multidrug-resistant pathogens will
also be of interest.
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